Jung Woo Park

Jung Woo Park

Auto-generated profile, based on publicly available information

Jung Woo Park

Department of Korean Medical Science, School of Korean Medicine, Pusan National University, Yangsan, Gyeongnam 50612, Republic of Korea

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2013 in Chemical Communications
Verified
Journal Article
Open access
PDF file
JPJung Woo Park
Jung Woo Park
YSYoung Jun Seo
Young Jun Seo
BKByeang Hyean Kim
Byeang Hyean Kim
Systematic modification of the 4A loop region of the Rb gene with PyA fluorophore units allows discrimination of the fluorescence signals corresponding to structural dynamics from single-stranded to i-motif structures.

30 November 2021 in Clinical and Experimental Otorhinolaryngology
Verified
Journal Article
Open access
PDF file
BKBo Gyung Kim
Bo Gyung Kim
JJJoo-Hyun Jung
Joo-Hyun Jung
MKMi-Jung Kim
Mi-Jung Kim
EMEun-Hye Moon
Eun-Hye Moon
JOJae-Hwan Oh
Jae-Hwan Oh
SKSeon Tae Kim
Seon Tae Kim
Objectives. Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant vascular disorder characterized by recurrent epistaxis, telangiectasia, and visceral arteriovenous malformations (AVMs). Activin A receptor-like type 1 (ACVRL1/ALK1) and endoglin (ENG) are the principal genes whose mutations cause HHT. No multicenter study has yet investigated correlations between genetic variations and clinical outcomes in Korean HHT patients.Methods. Seventy-two members from 40 families suspected to have HHT based on symptoms were genetically screened for pathogenic variants of ACVRL1 and ENG. Patients with genetically diagnosed HHT were also evaluated.Results. In the HHT genetic screening, 42 patients from 24 of the 40 families had genetic variants that met the pathogenic criteria (pathogenic very strong, pathogenic strong, pathogenic moderate, or pathogenic supporting) based on the American College of Medical Genetics and Genomics Standards and Guidelines for either ENG or ACVRL1: 26 from 12 families (50%) for ENG, and 16 from 12 families (50%) for ACVRL1. Diagnostic screening of 42 genetically positive HHT patients based on the Curaçao criteria revealed that 24 patients (57%) were classified as having definite HHT, 17 (41%) as having probable HHT, and 1 (2%) as unlikely to have HHT. Epistaxis was the most common clinical presentation (38/42, 90%), followed by visceral AVMs (24/42, 57%) and telangiectasia (21/42, 50%). Five patients (12%) did not have a family history of HHT clinical symptoms.Conclusion. Only approximately half of patients with ACVRL1 or ENG genetic variants could be clinically diagnosed as having definite HHT, suggesting that genetic screening is important to confirm the diagnosis.

2 August 2022 in Oncology Letters
Verified
Journal Article
Open access
PDF file
SLSeo-Yeon Lee
Seo-Yeon Lee
JPJung Hwa Park
Jung Hwa Park
KCKang-Hyun Cho
Kang-Hyun Cho
HKHui-Seon Kim
Hui-Seon Kim
HSHwa-Kyoung Shin
Hwa-Kyoung Shin
Glioblastoma multiforme (GBM) is the most frequently occurring malignant brain tumor in adults and is characterized by a high degree of vascularization. Glioblastoma cells communicate with their microenvironment and stimulate blood vessel formation to support tumor progression. It has previously been reported that isolinderalactone induces apoptosis in GBM cells and suppresses the growth of glioblastoma xenograft tumors in vivo. Furthermore, isolinderalactone has been shown to inhibit the hypoxia‑driven upregulation of vascular endothelial growth factor (VEGF) in U‑87 GBM cells and strongly reduce VEGF‑triggered angiogenesis in vitro and in vivo. In the present study, the direct angiogenic effect of GBM and the effect of isolinderalactone on tumor angiogenesis were investigated. Culture supernatants were obtained from U‑87 cells under normoxic or hypoxic conditions to provide normoxic conditioned medium (NCM) and hypoxic conditioned medium (HCM) respectively. The NCM and HCM were each used to treat to human brain microvascular endothelial cells (HBMECs), and their effects were observed using wounding migration and tube formation assays. HCM increased the migration and capillary‑like tube formation of HBMECs when compared with NCM, and treatment with isolinderalactone suppressed the HCM‑driven angiogenesis in vitro. Additionally, isolinderalactone decreased HCM‑triggered angiogenic sprouting in HBMECs in a 3D microfluidic device after the application of an HCM‑containing interstitial fluid flow. Furthermore, isolinderalactone strongly reduced HCM‑triggered angiogenesis in an in vivo Matrigel plug assay in mice. These findings provide evidence of angiogenesis inhibition by isolinderalactone, and demonstrate the anti-angiogenic effect of isolinderalactone against the direct angiogenic effect of GBM tumor cells.

31 March 2024 in The Journal of Korean Institute of Information Technology
Verified
Journal Article
Closed access
YLYongho Lee
Yongho Lee
JPJung Woo Park
Jung Woo Park
최근 들어 바이오 연구데이터의 축적 및 활용에 대한 국가적 중요성이 높아지고 있다. 이를 지원하기 위하여 공공영역의 체계적인 활용지원 모델 및 서비스 체계가 필요함에도 불구하고 지원 서비스의 개념 및 방향성에 대한 연구는 단편적으로 제시되어 통합 활용 서비스의 개념 설계가 부족한 실정이다. 본 연구는 활용 지원 서비스 개념 도출을 위한 바이오 연구데이터 활용 전주기 정의 및 공공 서비스 분류에 따라 미비한 서비스 개념을 종합적으로 제시한다. 제안한 서비스 개념은 총 8가지로 연구계획단계의 지원, 데이터 품질 평가/확인 단계 지원, 학습 데이터 변환 지원, 데이터 익명화 지원, 데이터 보강/보완 지원, 데이터 공유 지원, 데이터 파기지원에 대한 세부적 개념 정의 및 절차에 대해 서술하였다. 이를 통해 향후 활용 지원 서비스 시스템 개념 설계에 기여할 수 있을 것으로 생각된다.